BD Completes Acquisition of Straub Medical

FRANKLIN LAKES, N.J. (June 1, 2020) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has completed the acquisition of Straub Medical AG, a privately-held company that develops and sells medical atherectomy and thrombectomy devices that treat peripheral arterial disease (PAD) and venous disease. BD welcomes more than 80 new associates who add valuable experience and expertise as well as key technologies.

Currently available in the US, Europe, and other global regions, the Rotarex™S rotational atherectomy system is designed for use in acute, subacute and chronic vessel blockages. Using uniquely designed synchronized mechanisms of action, the Rotarex™S system provides clinicians with a single device to negotiate even complex lesions, all with a small equipment footprint that sets up in minutes.

The Aspirex™S thrombectomy system is designed to provide continuous aspiration and removal of thrombotic material from blood vessels. The Aspirex™S device is currently available in Europe and other global regions. The portfolio also includes additional adjunctive products used in the treatment of PAD and venous disease.

This acquisition allows BD to immediately deliver advanced technologies in both atherectomy and thrombectomy and further enhances BD's already strong portfolio of drug-coated, angioplasty and scoring balloons, stents, stent grafts and CTO crossing products for the treatment of PAD and venous disease.

"With our considerable expertise in endovascular technology and strong global infrastructure, BD is the right company to deliver Straub Medical's atherectomy and thrombectomy products to the market," said Steve Williamson, worldwide president, Peripheral Intervention at BD. "We are committed to improving the quality of life for the more than 200 million individuals worldwide affected by PAD and are committed to providing more tools for the challenges of managing venous disease. This acquisition allows us to help clinicians treat even more patients."

Gido Karges, CEO of Straub Medical, added "BD is the ideal strategic match for Straub Medical. With their complementary product portfolio and established global sales channels, BD offers treatment solutions to vascular specialists worldwide. We are excited to join BD in their mission of advancing the world of health."

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com.

About Straub Medical AG
Wangs (Switzerland) based Straub Medical AG is an internationally leading enterprise in the field of treating vascular disease. The company develops and manufactures medical devices for the treatment of arterial and venous disease. The company markets its products via a network of direct-sales subsidiaries and third-party distributors in more than 40 countries worldwide. Founded in 1997, Straub Medical AG operated as a family-held private corporation until its acquisition by BD. For more information, please visit www.straubmedical.com.

Contacts:

Troy Kirkpatrick
BD Public Relations
858.617.2361
troy.kirkpatrick@bd.com

Monique N. Dolecki
BD Investor Relations
201.847.5378
Monique_Dolecki@bd.com
